Standard conditions allowing efficient terminal differentiation of human erythroblasts in serum-free StemSpan medium
Factor . | Concentration . |
|---|---|
| Efficient terminal differentiation | |
| Erythropoietin | 10 U/mL |
| Insulin | 4 × 10-4 IE/mL |
| Human transferrin (iron saturated) | 1 mg/mL |
| ZK-112993 (glucocorticoid antagonist) | 3 μM |
| T3 | 1 μM |
| Human serum (commercial; Sigma) | 3% |
| Factors without any effect | |
| Cholesterol-rich lipid mix (Sigma) | 20-100 μg/mL |
| TGF-β | 1-25 pg |
| Activin | 1-25 pg |
| Fetal chicken serum | 10% |
| Chicken serum | 5%-10% |
| Human anemic serum | 2%-10% |
| Human cord blood serum | 2%-10% |
| Dihydrotestosterone | 1 μM |
| Progesterone | 1 μM |
| Estrogen | 1 μM |
| LY (PI-3-K inhibitor) | 1 μM |
| Fibronectin-coated plates | 20 μg/mL |
| Cpa (androgen antagonist) | 1 μM |
Factor . | Concentration . |
|---|---|
| Efficient terminal differentiation | |
| Erythropoietin | 10 U/mL |
| Insulin | 4 × 10-4 IE/mL |
| Human transferrin (iron saturated) | 1 mg/mL |
| ZK-112993 (glucocorticoid antagonist) | 3 μM |
| T3 | 1 μM |
| Human serum (commercial; Sigma) | 3% |
| Factors without any effect | |
| Cholesterol-rich lipid mix (Sigma) | 20-100 μg/mL |
| TGF-β | 1-25 pg |
| Activin | 1-25 pg |
| Fetal chicken serum | 10% |
| Chicken serum | 5%-10% |
| Human anemic serum | 2%-10% |
| Human cord blood serum | 2%-10% |
| Dihydrotestosterone | 1 μM |
| Progesterone | 1 μM |
| Estrogen | 1 μM |
| LY (PI-3-K inhibitor) | 1 μM |
| Fibronectin-coated plates | 20 μg/mL |
| Cpa (androgen antagonist) | 1 μM |